Tag: antibody-drug conjugate

Two FDA-approved antibody-drug conjugates (ADCs)—gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth) and belantamab mafodotin (Blenrep®; GSK)—were withdrawn from the U.S. market after confirmatory trials failed to verify...

Triple-negative breast cancer (TNBC) remains one of the most challenging and most malignant subtypes of breast cancer to treat. TNBC represents a heterogeneous group...

Becotatug Vedotin: First EGFR-Targeted ADC Approved in China for Recurrent or Metastatic Nasopharyngeal Carcinoma

Amanitin-Based ADCs: Transforming Mushroom Toxin into Precision Oncology

Antibody-Drug Conjugates in Gastric Cancer: Clinical Progress, Resistance, and the Road Ahead

How CDMOs Can Unlock One-step, High-Yield and Homogeneous ADC Manufacturing

The US Food and Drug Administration (FDA) has approved belantamab mafodotin (Blenrep®' GSK; see ADC Drugmap), an antibody-drug conjugate (ADC) comprising a humanized BCMA...

Data from the dose escalation portion of the Phase 1/2 study of JK06 in patients with unresectable locally advanced or metastatic cancer, including non-small cell lung cancer (NSCLC) and breast cancer, is being presented at the European Society for Medical Oncology (ESMO) Congress, being held October 17 - 21, 2025, in Berlin, Germany.[1]

ESMO 2025: Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care

ESMO 2025: First Clinical Data Presented for Tubulis' ADC Candidate, TUB-040